NHS England strikes deal to make innovative Multiple Sclerosis drug available, paving the way for NICE recommendation
Patients with Multiple Sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by NICE.
Ocrelizumab (also known as Ocrevus) is the first treatment that can modify or change the course of the disease to be available for patients who have primary progressive multiple sclerosis, where symptoms steadily increase over a period of months or years without periods of remission.
Clinical trial results show that ocrelizumab can slow the worsening of disability in people with the condition, helping patients stay able and active for longer.
Giving patients access to world class, cutting edge drugs and therapies is a key part of the NHS Long Term Plan.
Simon Stevens, chief executive of NHS England said:
“Today the NHS is making a significant advance in the care of people living with multiple sclerosis. This latest innovative deal is further proof that companies willing to work flexibly with the NHS can secure a constructive partnership that benefits both patients and taxpayers.”
The innovative deal between NHS England and Roche unlocks the final stage of NICE’s appraisal and opens the way for access to this important treatment.
It is estimated that 10,000-15,000 people have Primary progressive MS (PPMS) in the UK, of whom around 2,700 people could be eligible for treatment with ocrelizumab.
Multiple sclerosis is a lifelong condition which affects the brain and spinal cord. It affects everyone differently and there are a wide range of possible symptoms.
Primary progressive MS can have a substantial impact on the lives of people with the condition and their families.
Ocrelizumab will now be routinely available for eligible adults which, given the lack of other treatments for this form of MS, is great news for patients.
Ocrelizumab is given as an infusion during an outpatient appointment once every six months and costs around £19,000 per patient per year at full price.
NHS England has secured a commercial in confidence deal with Roche after tough negotiations on both sides.
With the deal, the cost-effectiveness estimates for ocrelizumab are in the range that NICE considers an acceptable use of NHS resources.
Previous arrangements would be down to industry proposing a price where NICE say yes or no to the drug being made available. NHS England now has more direct involvement with industry, working closely with NICE, to help to find deals that work for patients and taxpayers.
Latest News from
Pre-election guidance for the 2019 General Election07/11/2019 16:15:00
This pre-election guidance will help organisations make all staff aware of the implications on communications activities of the period prior to the 2019 general election.
New NHS online training to help people get home from hospital quicker05/11/2019 16:51:00
NHS England and Health Education England have today launched ActNow, an e-learning tool developed for health service and care staff to help them reduce hospital delays for patients.
Demand for NHS burns care soars over bonfire night and diwali04/11/2019 14:15:00
Top doctors from the NHS and St John Ambulance have teamed up to urge revellers to stay safe during Guy Fawkes Night and Diwali celebrations, as new figures reveal thousands end up in hospital each year due to firework and bonfire injuries.
Public back NHS plans for new rapid care measures01/11/2019 14:25:00
England’s top doctor has welcomed new polling showing that patients and the public support NHS proposals focussing on fast treatment for those who need it in A&E.
NHS ramps up drive to increase uptake of lifesaving vaccines28/10/2019 09:15:00
More lifesaving vaccines should be provided in convenient locations for parents to drive uptake, a new NHS review shows.
NHS England concludes wide-ranging deal for cystic fibrosis drugs24/10/2019 12:20:00
NHS England has today announced it has secured a definitive agreement with Vertex Pharmaceuticals to make available all three of their UK-licensed cystic fibrosis medicines.
Tens of thousands given life changing diabetes monitors thanks to the NHS Long Term Plan22/10/2019 14:15:00
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan.
World Antibiotic Awareness Week, 18-22 November22/10/2019 09:15:00
World Antibiotic Awareness Week (WAAW) aims to increase awareness of antibiotic resistance as a global problem, and to promote best practices among the general public, health workers and policy-makers to avoid the further emergence and spread of antibiotic resistance.